Nicole Lamanna

8.6k total citations
113 papers, 1.8k citations indexed

About

Nicole Lamanna is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Nicole Lamanna has authored 113 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Genetics, 62 papers in Pathology and Forensic Medicine and 36 papers in Immunology. Recurrent topics in Nicole Lamanna's work include Chronic Lymphocytic Leukemia Research (104 papers), Lymphoma Diagnosis and Treatment (62 papers) and Immunodeficiency and Autoimmune Disorders (29 papers). Nicole Lamanna is often cited by papers focused on Chronic Lymphocytic Leukemia Research (104 papers), Lymphoma Diagnosis and Treatment (62 papers) and Immunodeficiency and Autoimmune Disorders (29 papers). Nicole Lamanna collaborates with scholars based in United States, Australia and Germany. Nicole Lamanna's co-authors include Andrew Lipsky, Mark A. Weiss, Steven Coutré, Andrew D. Zelenetz, Susan O’Brien, Thomas J. Kipps, Ian W. Flinn, P. Maslak, Matthew S. Davids and Jalaja Potluri and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Nicole Lamanna

107 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicole Lamanna United States	21	1.4k	1.1k	536	428	343	113	1.8k
Karim Maloum France	19	1.2k 0.9×	920 0.8×	612 1.1×	336 0.8×	205 0.6×	51	1.6k
Monali Desai United States	7	950 0.7×	617 0.5×	362 0.7×	446 1.0×	402 1.2×	20	1.6k
Cheson Bd United States	10	1.5k 1.1×	1.3k 1.1×	788 1.5×	284 0.7×	426 1.2×	59	2.0k
Sílvia Marcé Spain	12	1.1k 0.8×	877 0.8×	599 1.1×	240 0.6×	306 0.9×	20	1.6k
Jacques‐Louis Binet France	12	1.3k 1.0×	1.1k 1.0×	684 1.3×	330 0.8×	277 0.8×	21	1.8k
Jerzy Z. Błoński Poland	21	797 0.6×	642 0.6×	403 0.8×	151 0.4×	291 0.8×	75	1.2k
Herbert Eradat United States	17	564 0.4×	531 0.5×	270 0.5×	181 0.4×	257 0.7×	60	966
Joanna Góra‐Tybor Poland	18	733 0.5×	381 0.3×	164 0.3×	594 1.4×	218 0.6×	82	1.2k
Evdoxia Hatjiharissi United States	21	726 0.5×	608 0.5×	555 1.0×	727 1.7×	649 1.9×	86	2.0k
Leonard T. Heffner United States	21	561 0.4×	464 0.4×	227 0.4×	996 2.3×	784 2.3×	86	1.8k

Countries citing papers authored by Nicole Lamanna

Since Specialization

Citations

This map shows the geographic impact of Nicole Lamanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicole Lamanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicole Lamanna more than expected).

Fields of papers citing papers by Nicole Lamanna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicole Lamanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicole Lamanna. The network helps show where Nicole Lamanna may publish in the future.

Co-authorship network of co-authors of Nicole Lamanna

This figure shows the co-authorship network connecting the top 25 collaborators of Nicole Lamanna. A scholar is included among the top collaborators of Nicole Lamanna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicole Lamanna. Nicole Lamanna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shadman, Mazyar, Jennifer R. Brown, Heather Burnett, et al.. (2024). Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).. Journal of Clinical Oncology. 42(16_suppl). 7048–7048. 1 indexed citations

Roeker, Lindsey E., Jennifer A. Woyach, Chan Y. Cheah, et al.. (2024). Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 144(13). 1374–1386. 11 indexed citations

Shadman, Mazyar, Alessandra Tedeschi, Nicole Lamanna, et al.. (2023). Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison. Blood. 142(Supplement 1). 4655–4655. 1 indexed citations

Eichhorst, Barbara, Nicole Lamanna, Susan O’Brien, et al.. (2023). Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of life. Hematological Oncology. 41(S2). 463–464.

Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology. 41(S2). 239–242. 8 indexed citations

Stewart, Chris, Neil A. Bailey, John C. Byrd, et al.. (2021). Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD). Blood. 138(Supplement 1). 1927–1927. 2 indexed citations

Davids, Matthew S., Bryone J. Kuss, Peter Hillmen, et al.. (2020). Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. 26(9). 2096–2103. 33 indexed citations

Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2020). Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. Blood. 136(Supplement 1). 45–46. 5 indexed citations

Ujjani, Chaitra S., Anthony R. Mato, Brian T. Hill, et al.. (2020). <p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. SHILAP Revista de lepidopterología. Volume 10. 1–5. 6 indexed citations

10.

Hillmen, Peter, Jennifer R. Brown, John C. Byrd, et al.. (2019). Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 134(Supplement_1). 4307–4307. 2 indexed citations

11.

Lamanna, Nicole, Árpád Illés, Gabriel Étienne, et al.. (2019). Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial. American Journal of Hematology. 94. 1 indexed citations

12.

Kuss, Bryone J., Matthew S. Davids, Peter Hillmen, et al.. (2018). The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. Journal of Clinical Oncology. 36(15_suppl). 7533–7533. 2 indexed citations

13.

Mato, Anthony R., Chadi Nabhan, Neil E. Kay, et al.. (2017). Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clinical Lymphoma Myeloma & Leukemia. 18(2). 114–124.e2. 24 indexed citations

14.

Hillmen, Peter, Christelle Ferrá, José A. García‐Marco, et al.. (2016). Idelalisib in Combination with Bendamustine/rituximab Improves Overall Survival in Patients with Relapsed/refractory Cll: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. Haematologica. 101. 433–433. 2 indexed citations

15.

Mato, Anthony R., Christopher R. Flowers, Charles M. Farber, et al.. (2015). Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.. Journal of Clinical Oncology. 33(15_suppl). 7013–7013. 2 indexed citations

16.

Saif, Muhammad Wasif, Chris H. Takimoto, Monica Mita, et al.. (2013). A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(2). 445–455. 38 indexed citations

17.

Lamanna, Nicole. (2012). Treatment of Older Patients with Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports. 7(1). 21–25. 7 indexed citations

18.

Pashos, Chris L., Christopher R. Flowers, Mark A. Weiss, et al.. (2011). Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. Blood. 118(21). 2085–2085. 1 indexed citations

19.

Weiss, Mark A. & Nicole Lamanna. (2006). In adult ALL, less is now more. Blood. 107(3). 852–853. 4 indexed citations

20.

Lamanna, Nicole & Mark A. Weiss. (2004). Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia.. PubMed. 3(1). 40–6. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact